비교리스트

 카트 문의
시장보고서
상품코드
1544104

세계의 예측 검사와 전조 검사 시장

Predictive and Presymptomatic Testing
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 159 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 예측 검사와 전조 검사 시장은 2030년까지 104억 달러에 도달

2023년에 55억 달러로 추정되는 세계의 예측 검사와 전조 검사 시장은 2030년에는 104억 달러에 달하며, 분석 기간인 2023-2030년 CAGR은 9.5%로 성장할 것으로 예측됩니다.

미국 시장은 14억 달러, 중국은 CAGR 12.6%로 성장 예측

미국의 예측 검사와 전조 검사 시장은 2023년에 14억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 24억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년 CAGR은 12.6%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 6.5%와 7.5%로 예측됩니다. 유럽에서는 독일이 CAGR 7.4%로 성장할 것으로 예측됩니다.

세계의 예측 검사와 전조 검사 시장 - 주요 동향과 촉진요인 정리

예측 검사와 전조 검사 : 건강 리스크 예측

예측 검사와 전조 검사에서는 증상이 나타나기 전에 유전자 검사 및 기타 진단 검사를 통해 개인의 특정 질병 발병 위험을 평가합니다. 이러한 검사는 DNA, 단백질 및 기타 바이오마커를 분석하여 암, 심장병, 신경 퇴행성 질환과 같은 질병의 발병 가능성 증가와 관련된 돌연변이 및 기타 지표를 식별합니다. 예측 검사는 일반적으로 특정 질환의 가족력이 있는 사람들에게 사용되며, 위험을 줄이거나 발병을 늦추기 위한 조기 개입 및 예방 조치를 가능하게 합니다. 반면, 전증상 검사는 무증상인 개인이 가족 내에 존재하는 것으로 알려진 유전성 질환의 발병 여부를 판단하는 데 사용됩니다. 이러한 검사의 주요 목적은 개인과 의료 서비스 프로바이더에게 의학적 결정과 생활 방식 변경을 안내하고 궁극적으로 건강 결과를 개선하는 데 도움이 되는 귀중한 정보를 제공하는 것입니다.

기술의 발전은 어떻게 예측 검사와 전조 검사를 향상시키고 있는가?

기술의 발전으로 예측 및 예후 검사의 정확성, 접근성 및 범위가 크게 향상되었습니다. 차세대 염기서열 분석기(NGS)의 발전으로 유전체의 큰 부분을 빠르고 비용 효율적으로 분석할 수 있게 되어 질병 위험과 관련된 유전적 변이를 보다 광범위하게 식별할 수 있게 되었습니다. 보다 민감하고 특이적인 바이오마커의 개발로 증상이 나타나기 전에도 질병의 초기 징후를 감지할 수 있는 능력이 향상되었습니다. 또한 생물정보학 및 머신러닝 알고리즘의 통합은 유전자 데이터 분석을 강화하여 보다 정확한 위험 평가와 개인화된 지식을 제공할 수 있게 되었습니다. 또한 소비자 직접 판매 유전자 검사 서비스의 등장으로 예측 검사에 대한 접근성이 높아져 개인이 전통적인 임상 현장 없이도 자신의 건강 위험에 대한 인사이트을 얻을 수 있게 되었습니다. 이러한 기술적 개선으로 예측 검사와 예후 검사의 용도와 영향력이 확대되어 사전 예방적 헬스케어를 위한 귀중한 툴이 되고 있습니다.

예측 검사와 전조 검사의 주요 용도와 장점은?

예측 검사와 예후 검사는 다양한 의료 분야에 적용되어 질병 예방과 관리를 강화하는 많은 이점을 제공합니다. 종양학에서는 유방암이나 난소암과 관련된 BRCA1/2 돌연변이와 같은 유전성 암의 위험이 높은 개인을 식별하여 조기 감시 및 예방 조치를 취할 수 있도록 하는 데 예측 검사를 사용하고 있습니다. 심장학에서는 유전자 검사를 통해 가족성 고콜레스테롤혈증 등과 관련된 돌연변이를 식별하여 심장병 예방을 위한 개입을 유도할 수 있습니다. 신경학에서는 무증상 검사를 통해 헌팅턴병과 같은 질환을 조기에 진단하여 가족계획과 생활습관 선택에 도움을 줄 수 있습니다. 또한 약물유전체학에서 예측 검사는 특정 약물에 대한 개인의 반응을 결정하는 데 사용되어 효능을 최적화하고 부작용을 최소화하는 맞춤 치료 계획을 수립할 수 있습니다. 예측 및 예후 검사의 주요 장점은 증상이 나타나기 전에 질병 위험을 식별할 수 있으며, 조기 개입, 개인화된 의료 서비스, 환자 결과 개선이 가능하다는 점입니다. 이러한 검사는 개인의 유전적 소인에 대한 귀중한 인사이트을 제공함으로써 적극적인 헬스케어와 정보에 입각한 의사결정을 촉진합니다.

예측 검사 및 전조 검사 시장의 성장을 가속하는 요인은 무엇인가?

예측 및 예측 검사 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 질병 위험에서 유전의 역할에 대한 인식이 높아지고 맞춤형 의료에 대한 수요가 증가함에 따라 이러한 검사가 맞춤 치료 및 예방 전략을 안내할 수 있는 귀중한 정보를 제공하므로 중요한 촉진제가 되고 있습니다. 유전자 검사의 정확성, 신속성, 경제성을 향상시키는 기술 발전도 시장 성장에 기여하고 있습니다. 소비자 직접 유전자 검사 서비스의 확대로 일반인들이 보다 쉽게 이용할 수 있게 됨에 따라 수요를 더욱 촉진하고 있습니다. 또한 예방 의료 및 질병 조기 발견에 대한 관심이 높아지면서 예측 및 예후 검사의 채택이 증가하고 있으며, AI 및 생물정보학과 같은 고급 데이터 분석 툴의 통합은 이러한 검사의 유용성과 정확성을 향상시켜 지속적인 성장을 가속하고 있습니다. 이러한 요인들은 유전자 검사 기술의 지속적인 혁신과 함께 예측 및 예후 검사 시장의 지속적인 성장을 촉진하고 있습니다.

조사 대상 기업의 예(주목 14사)

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC(DirectLabs)
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.09.04

Global Predictive and Presymptomatic Testing Market to Reach US$10.4 Billion by 2030

The global market for Predictive and Presymptomatic Testing estimated at US$5.5 Billion in the year 2023, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 12.6% CAGR

The Predictive and Presymptomatic Testing market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global Predictive and Presymptomatic Testing Market - Key Trends and Drivers Summarized

Predictive and Presymptomatic Testing: Anticipating Health Risks

Predictive and presymptomatic testing involves the use of genetic and other diagnostic tests to assess an individual's risk of developing a particular disease before symptoms appear. These tests analyze DNA, proteins, and other biomarkers to identify mutations or other indicators that are associated with an increased likelihood of developing conditions such as cancer, heart disease, or neurodegenerative disorders. Predictive testing is typically used in individuals with a family history of a specific disease, allowing for early intervention and preventive measures that can reduce the risk or delay the onset of the disease. Presymptomatic testing, on the other hand, is used to determine whether an asymptomatic individual will develop a genetic disorder that is known to be present in the family. The primary purpose of these tests is to provide individuals and healthcare providers with valuable information that can guide medical decisions and lifestyle changes, ultimately improving health outcomes.

How Are Technological Advancements Enhancing Predictive and Presymptomatic Testing?

Technological advancements have significantly enhanced the accuracy, accessibility, and scope of predictive and presymptomatic testing. Advances in next-generation sequencing (NGS) have made it possible to analyze large segments of the genome quickly and cost-effectively, allowing for the identification of a broader range of genetic variants associated with disease risk. The development of more sensitive and specific biomarkers has improved the ability to detect early signs of disease, even before symptoms emerge. Additionally, the integration of bioinformatics and machine learning algorithms has enhanced the interpretation of genetic data, providing more accurate risk assessments and personalized insights. The rise of direct-to-consumer genetic testing services has also increased access to predictive testing, enabling individuals to gain insights into their health risks without the need for traditional clinical settings. These technological improvements have expanded the applications and impact of predictive and presymptomatic testing, making it a valuable tool for proactive healthcare.

What Are the Key Applications and Benefits of Predictive and Presymptomatic Testing?

Predictive and presymptomatic testing is applied in various areas of healthcare, offering numerous benefits that enhance disease prevention and management. In oncology, predictive testing is used to identify individuals at high risk of hereditary cancers, such as BRCA1/2 mutations associated with breast and ovarian cancer, enabling early surveillance and preventive measures. In cardiology, genetic testing can identify mutations linked to conditions like familial hypercholesterolemia, guiding interventions to prevent heart disease. Neurology benefits from presymptomatic testing for disorders such as Huntington's disease, where early diagnosis can inform family planning and lifestyle choices. Additionally, predictive testing is used in pharmacogenomics to determine how individuals will respond to specific medications, allowing for personalized treatment plans that optimize efficacy and minimize adverse effects. The primary benefits of predictive and presymptomatic testing include the ability to identify disease risks before symptoms appear, enabling early intervention, personalized healthcare, and improved patient outcomes. By providing valuable insights into an individual's genetic predispositions, these tests empower proactive health management and informed decision-making.

What Factors Are Driving the Growth in the Predictive and Presymptomatic Testing Market?

The growth in the predictive and presymptomatic testing market is driven by several factors. The increasing awareness of the role of genetics in disease risk and the growing demand for personalized healthcare are significant drivers, as these tests provide valuable information that can guide individualized treatment and prevention strategies. Technological advancements that enhance the accuracy, speed, and affordability of genetic testing are also propelling market growth. The expansion of direct-to-consumer genetic testing services, which make these tests more accessible to the general population, is further boosting demand. Additionally, the rising focus on preventive healthcare and the early detection of diseases are contributing to the increased adoption of predictive and presymptomatic testing. The integration of advanced data analysis tools, such as AI and bioinformatics, is enhancing the utility and accuracy of these tests, driving their continued growth. These factors, coupled with the ongoing innovation in genetic testing technologies, are driving the sustained growth of the predictive and presymptomatic testing market.

Select Competitors (Total 14 Featured) -

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC (DirectLabs)
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Predictive and Presymptomatic Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Genetic Testing Propel Market Dynamics
    • Increasing Awareness of Preventive Healthcare Expands Addressable Market Opportunity
    • Government Initiatives for Genomic Research Strengthens Business Case
    • Growing Adoption of Direct-to-Consumer Genetic Tests Throws the Spotlight on Innovation
    • Focus on Early Disease Detection and Prevention Accelerates Market Demand
    • Expansion of Genetic Counseling Services Boosts Market Prospects
    • Rising Prevalence of Genetic Disorders Enhances Market Growth
    • Integration of AI and Big Data in Genetic Analysis Drives Market Dynamics
    • Increasing Investments in Genomic Research and Development Propels Market Expansion
    • Focus on Reducing Healthcare Costs Sustains Market Growth
    • Growing Use of Predictive Testing in Oncology Expands Market Reach
    • Focus on Regulatory Approvals and Reimbursement Policies Enhances Market Opportunities
    • Rising Consumer Interest in Ancestry and Health Insights Spurs Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Predictive and Presymptomatic Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제